Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

h being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(R); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Contact:
    Michael W. Rogers                    Robin L. DeCarlo
    EVP and Chief Financial Officer      Director, Corporate Communications
    (781) 861-8444                       (781) 402-3405



                        INDEVUS PHARMACEUTICALS, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
             For the three and twelve months ended September 30,
                                2008 and 2007
                 (Amounts in thousands except per share data)

                                         For the three       For the twelve
                                          months ended        months ended
                  
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Lione, one of,the largest intellectual property law firms in ... Addy has been named one of the Top,10 Illinois ... Politics,magazine., Intellectual property law, specifically patent law, traditionally ... practice, Ms. Addy is,among the most recognized patent attorneys ...
... Human Genome,Sciences, Inc. (Nasdaq: HGSI ) today ... its financial results for the year ended,December 31, 2007. ... 25, 2008, after the capital markets close., (Logo: ... be hosted by senior management and will be,held on ...
... Graceway Pharmaceuticals, LLC,("Graceway"), a portfolio company of ... acquired all of the assets related to Estrasorb(R),(estradiol ... (Nasdaq: NVAX ) and Allergan, Inc. ("Allergan") ... treatment of moderate to severe vasomotor,symptoms associated with ...
Cached Biology Technology:Meredith Martin Addy Named One of Top 10 Illinois 'Super Lawyers' for 2008 2Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results 2Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX) 2
(Date:7/11/2014)... Sweden, have explored two different ways that allow ... to the formation of oxygen molecules in photosynthesis. ... scientific journal Nature Communications . , "The ... catalysts for water oxidation, which are key components ... storage of solar energy in fuels like hydrogen, ...
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... LONDON , February 11 De ... today announced,that it will design and roll-out East Africa,s ... part of the ongoing Rwandan National ID project,(NID). The plans for ... driver,s licence, are already underway. The first eID,documents are expected to ...
... , A few grass species provide the bulk of our ... sustainable energy and feedstock production. However there are significant barriers ... gene function and their large and complex genomes. , Now, ... international consortium led by the John Innes Centre, the US ...
... N.C. Any way you look at it -- by ... creepy crawlies called arthropods dominate planet Earth. Because of their ... figure out the family relationships that link lobsters to millipedes ... first. In a scientific and technological tour de force ...
Cached Biology News:De La Rue to Provide East Africa's First eID Project 2De La Rue to Provide East Africa's First eID Project 3First member of the wheat and barley group of grasses is sequenced 2Study finds surprising new branches on arthropod family tree 2Study finds surprising new branches on arthropod family tree 3
... from 2 mM sodium phosphate buffer, pH ... D is a major lysosomal aspartyl protease ... kDa proenzyme. Overexpression of cathepsin D in ... risk of relapse and metastasis. Cathepsin D ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
... Automation Buffer is a concentrated formulation of ... employing capillary action technology, as well as ... collaboration with David Brigati M.D., Department of ... This buffer is recommended for all the ...
... Intended for users requiring mass detection ... linear MALDI TOF Mass spectrometer is ... applications and for high performance mass ... QA/QC, SNP analysis, protein detection, micro-satellite ...
Biology Products: